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Background: Prostate cancer is the most common cancer in British men but its aetiology is not well understood. We aimed to
identify risk factors for prostate cancer in British males.
Methods: We studied 219 335 men from the UK Biobank study who were free from cancer at baseline. Exposure data were
collected at recruitment. Prostate cancer risk by the different exposures was estimated using multivariable-adjusted Cox
proportional hazards models.
Results: In all, 4575 incident cases of prostate cancer occurred during 5.6 years of follow-up. Prostate cancer risk was positively
associated with the following: black ethnicity (hazard ratio black vs white¼ 2.61, 95% confidence interval¼ 2.10–3.24); having ever
had a prostate-specific antigen test (1.31, 1.23–1.40); being diagnosed with an enlarged prostate (1.54, 1.38–1.71); and having a
family history of prostate cancer (1.94, 1.77–2.13). Conversely, Asian ethnicity (Asian vs white hazard ratio¼ 0.62, 0.47–0.83), excess
adiposity (body mass index (X35 vs o25 kgm 2¼ 0.75, 0.64–0.88) and body fat (X30.1 vs o20.5%¼ 0.81, 0.73–0.89)),
cigarette smoking (current vs never smokers¼ 0.85, 0.77–0.95), having diabetes (0.70, 0.62–0.80), and never having had children
(0.89, 0.81–0.97) or sexual intercourse (0.53, 0.33–0.84) were related to a lower risk.
Conclusions: In this new large British prospective study, we identified associations with already-established, putative and possible
novel risk factors for being diagnosed with prostate cancer. Future research will examine associations by tumour characteristics.
Prostate cancer is the most common cancer in men in the United
Kingdom (UK), with 40 300 cases diagnosed in 2015 (ONS, 2017).
The aetiology of prostate cancer is not well understood, and the
well-established risk factors age, ethnicity, and family history of the
disease are not modifiable (Cuzick et al, 2014; WCRF/AICR, 2014).
However, there is evidence that circulating insulin-like growth
factor-I (IGF-I), which is influenced by environmental factors, is
related to higher prostate cancer risk (Travis et al, 2016), and the
latest World Cancer Research Fund meta-analysis of prospective
studies concluded that it is probable that obesity is associated with
a higher incidence of aggressive prostate cancer. While there is
limited epidemiological evidence for other lifestyle risk factors for
prostate cancer (WCRF/AICR, 2014), the relatively high variation
in incidence rates worldwide suggests that differences in exposure
to environmental factors may have a role in prostate cancer
development, although some of the variation is due to differences
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between countries in prostate-specific antigen (PSA) testing (Ferlay
et al, 2015).
The UK Biobank cohort is an important new resource for the
study of cancer aetiology. We report here the first results from this
cohort on the association between prostate cancer incidence and
potential risk factors, including socio-demographic, anthropo-
metric and lifestyle factors, health status, prostate-specific factors
prior to the recruitment, sexual history, early life characteristics,
hair colour, and balding pattern. We also tested whether these
associations vary by time to diagnosis.
MATERIALS AND METHODS
Study design. The UK Biobank is a prospective study designed to
be a resource for research into the causes of disease in middle and
old age. The study protocol and information about data access are
available online (http://www.ukbiobank.ac.uk/wp-content/uploads/
2011/11/UK-Biobank-Protocol.pdf) and more details of the
recruitment and study design have been published elsewhere
(Sudlow et al, 2015). In brief, all participants were registered with
the UK National Health Service (NHS) and lived withinB25miles
(40 km) of one of the assessment centres. The UK Biobank invited
B9.2 million people to participate through postal invitation with a
telephone follow-up, with a response rate of 5.7%. A total of
503 317 men and women aged 40–69 years were recruited in 22
assessment centres across England, Wales and Scotland, between
2006 and 2010. In all, 608 participants have subsequently
withdrawn from the study and their data were not available for
analysis. The UK Biobank study was approved by the North West
Multi-Centre Research Ethics Committee (reference number 06/
MRE08/65), and at recruitment all participants gave informed
consent to participate in UK Biobank and be followed-up, using a
signature capture device.
After excluding 9835 men with prevalent cancer (except C44:
non-melanoma skin cancer), and 2 men censored on entry day,
these analyses included a total of 219 335 men (Supplementary
Figure 1).
Exposure assessment. Participants provided detailed self-reported
data via a touch screen questionnaire and a verbal interview with a
trained nurse at the assessment centres at baseline (Sudlow et al,
2015), and a wide range of physical measurements (e.g., body mass
index (BMI) and including bioimpedance) and biological samples
were collected (Sudlow et al, 2015). Information about the
assessment procedure is available at http://www.ukbiobank.ac.uk/.
Exposure data included information on socio-demographic
factors (region, Townsend deprivation index, education level,
ethnicity, employment, and living with a wife or partner),
anthropometric measurements (standing height, weight, BMI,
percentage body fat, waist and hip circumferences, waist to hip
ratio (WHR) (UK-Biobank, 2014)), lifestyle characteristics (smok-
ing status, alcohol consumption, and physical activity), health-
related factors (vasectomy, hypertension, and diabetes), prostate-
specific factors prior to recruitment (PSA test, enlarged prostate,
and family history of prostate cancer), sexual history (number of
children, age at first sexual intercourse, lifetime heterosexual
partners, same-sex intercourse, and lifetime number of same-sex
partners), early life factors (puberty as defined by age of first facial
hair, relative age voice broke, and comparative body size and
height at age 10 years), and hair colour and balding pattern.
Detailed information regarding how these variables were collected
is given in the Supplementary Methods.
Outcome assessment. Men were followed-up until the censoring
date (30 September 2014 in England and Wales, and 31 December
2014 in Scotland) via record linkage to the NHS Central Register,
which provides information on cancer registrations and deaths.
The end point included in these analyses is first diagnosis of
prostate cancer (International Classification of Diseases Tenth
revision codes: C61; (WHO, 2010)) or death from prostate cancer,
whichever was first. Person-years were calculated from the date of
recruitment to the date of cancer registration (first malignant
neoplasm, except non-melanoma skin cancer (ICD-10 C44)),
death, or the censoring date, whichever occurred first.
Statistical analysis. Cox proportional hazards models were used
to calculate hazard ratios (HRs) and 95% confidence intervals (CIs)
for prostate cancer risk, using age as the underlying time variable.
All analyses were stratified by geographical region of recruitment
(10 UK regions, except for when region was the main exposure of
interest) and age (o45, 45–49, 50–54, 55–59, 60–64,X65 years) at
recruitment. Exposure variables (socio-demographic factors,
anthropometric measurements, lifestyle characteristics, health
status, prostate-specific factors prior to recruitment, sexual history,
early life factors, and hair colour and balding pattern) were divided
into categories based on their distribution at baseline in the whole
cohort (categories for each exposure are explained in detailed in
Supplementary Methods). Missing and/or unknown values of the
exposure of interest were not included in the analyses, but missing
and/or unknown values were assigned to a separate category when
the variable was included as a covariate. As these are the first
analyses on the association between potential risk factors and
incidence of total prostate cancer in UK Biobank, potential
confounders were first identified a priori based on possible risk
factors for prostate cancer that have some support in the literature
(Sutcliffe & Colditz, 2013; Cuzick et al, 2014; WCRF/AICR, 2014;
Rider et al, 2016).
Minimally adjusted Cox regression models were performed to
identify statistically important covariates from the a priori
potential confounders. On the basis of results from the minimally
adjusted Cox regression analyses, the multivariable-adjusted model
was additionally adjusted for Townsend deprivation score (fifths,
unknown (0.1%)), ethnicity (white, mixed background, Asian,
black, other, and unknown (0.7%)), lives with a wife or partner (no,
yes), BMI (o25, X25–o30, X30–o35, X35 kgm 2, and
unknown (0.6%)), cigarette smoking (never, former, current, and
unknown (0.7%)), physical activity (low (0–o10 metabolic
equivalents (METs) per week), moderate (X10–o50 METs per
week), high (X50 METs per week), and unknown (3.7%)), diabetes
(no, yes, and unknown (0.6%)), enlarged prostate (no or unknown,
and yes), and family history of prostate cancer (no, yes (brother or
father), and unknown (45.1%)). For each adjustment variable,
missing values were assigned to a separate category. Body mass
index was not included in the multivariable-adjusted model when
fat mass, waist circumference, and WHR were the main exposure
variables.
P-values from the multivariable-adjusted model for the associa-
tion of each exposure with prostate cancer risk were calculated as
follows: P-values for likelihood ratio tests for variables with
more than two categories (categorical variables) were obtained
comparing the model with and without the variable of interest;
P-values for dichotomous variables were obtained comparing the
reference category to the other category in the model; and P-values
for trend were obtained using a pseudo-continuous variable
equal to the median value in each category for continuous
variables. The proportional hazards assumption was tested
using time-varying covariates and Schoenfeld residuals and
revealed no evidence of deviation from the proportional hazards
assumption.
Sensitivity analyses were performed to test for heterogeneity in
the associations with risk by time between recruitment and
diagnosis (o2 and X2 years) to examine whether there were
associations for cancers diagnosed shortly after recruitment, which
could indicate reverse causality. For this purpose, we fitted
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stratified Cox models based on competing risks and compared the
risk coefficients and s.e.’s in the subgroups of interest (o2 or X2
years between recruitment and diagnosis). All analyses were
performed using Stata version 14.1 (Stata Corporation, College
Station, TX, USA), all tests of significance were two-sided, and
P-values o0.05 were considered statistically significant.
RESULTS
Participants’ characteristics. A total of 4575 men were diagnosed
with prostate cancer after a mean 5.6 years (s.d., 1.0 years) follow-
up. Table 1 shows the characteristics of the study population at
baseline. The mean age at recruitment was 56.5 years (s.d., 8.2
years) and the mean BMI was 27.8 kgm 2 (s.d., 4.2). Among all
participants, 12.4% reported that they were current cigarette
smokers, and 43.2% reported drinking at least 20 g of alcohol per
day. Physical inactivity was reported by 27.6% of men. Diabetes
was reported by 6.9% of men. Regarding prostate-specific factors
prior to recruitment, 27.6% of men reported having had at least
one PSA test and 7.5% of men had a family history of prostate
cancer.
Table 2 shows the HRs of prostate cancer in relation to socio-
demographic factors, anthropometric factors, and lifestyle factors
before and after adjusting for multiple factors. There were no
marked differences between the minimally and multivariable-
adjusted models. After multivariable adjustment, men living in
North-West England, North-East England, Yorkshire & the
Humber, and in South-West England were significantly less likely
to be diagnosed with prostate cancer than men living in London.
There was no evidence for an association between living in a
deprived area, having higher education, being unemployed, or
living with a partner and prostate cancer risk. Compared to men of
white ethnicity, Asians had a lower risk (HR¼ 0.62, 95% CI 0.47–
0.83) and black men had a higher risk (2.61, 2.10–3.24) of prostate
cancer.
Height was not associated with prostate cancer risk in the
multivariable-adjusted model (Table 2). Obesity (BMI X30–o35
vso25 kgm 2: HR¼ 0.88, 95% CI 0.81–0.97) and morbid obesity
(BMI X35 vs o25 kgm 2¼ 0.75, 0.64–0.88), high body fat
percentage (HR for the highest vs the lowest fifth¼ 0.81,
0.73–0.89), high waist circumference (HR for the highest vs the
lowest fifth¼ 0.90, 0.82–0.99), and high WHR (HR for the highest
vs the lowest fifth¼ 0.87, 0.79–0.96) were all significantly inversely
associated with prostate cancer risk.
Table 1. Baseline characteristics of all men included in the analysis and of men who developed prostate cancer
Characteristics All men Men who developed prostate cancer
No. of men 219335 4575
Socio-demographic
Age at recruitment (years), mean (s.d.) 56.5 (8.2) 62.4 (5.2)
Most deprived quintile, % (n) 20.0 (43 809) 15.7 (719)
No qualifications, % (n) 13.5 (29 593) 11.5 (528)
Black ethnicity, % (n) 1.5 (3279) 1.9 (89)
Not in paid/self-employment, % (n) 38.9 (85 223) 41.6 (1904)
Living with partner, % (n) 76.1 (166 967) 79.3 (3630)
Anthropometric
Height (cm), mean (s.d.) 175.6 (6.8) 175.1 (6.7)
BMI (kgm 2), mean (s.d.) 27.8 (4.3) 27.5 (3.8)
Body fat (%), mean (s.d.) 25.3 (5.8) 25.4 (5.5)
Waist circumference (cm), mean (s.d.) 96.9 (11.4) 96.9 (10.6)
Waist to hip ratio, mean (s.d.) 0.936 (0.065) 0.939 (0.064)
Lifestyle
Current cigarette smokers, % (n) 12.4 (27 428) 9.0 (417)
Drinking alcohol X20g per day, % (n) 43.2 (94 750) 42.2 (1930)
Low physical activity (0–o10 METs per week), % (n) 27.6 (60 589) 26.1 (1196)
Self-reported health status
Vasectomy, % (n) 5.2 (11 366) 5.1 (232)
Hypertension, % (n) 52.1 (114 193) 59.0 (2700)
Diabetes, % (n) 6.9 (15 191) 5.9 (270)
Prostate specific factors prior to recruitment
Ever had a PSA test, % (n) 27.6 (60 646) 46.6 (2133)
Enlarged prostate, % (n) 3.2 (7093) 7.8 (359)
Family history of prostate cancer, % (n) 7.5 (16 449) 13.1 (599)
Sexual history
Number of children, median (s.d.) 2.0 (1.4) 2.0 (1.3)
Age at first sexual intercourse (years), median (s.d.) 18.0 (6.2) 19.0 (6.2)
Lifetime number of heterosexual partners, median (s.d.) 3.0 (92.2) 2.0 (45.1)
Same-sex intercourse, % (n) 3.9 (8576) 3.2 (146)
Lifetime number of same-sex partners, median (s.d.) 2.0 (384.9) 2.0 (196.4)
Early life
Age at first facial hair older than average, % (n) 12.3 (27 009) 10.0 (459)
Age voice broke older than average, % (n) 5.4 (11 861) 4.2 (194)
Plumper than average at age 10, % (n) 13.4 (29 305) 11.7 (536)
Taller than average at age 10, % (n) 24.6 (53 953) 24.4 (1115)
Hair colour and pattern
Red hair colour, % (n) 3.5 (7726) 3.1 (144)
Hair/balding pattern 4,a % (n) 17.8 (39 051) 19.3 (882)
Abbreviations: BMI¼body mass index; PSA¼prostate-specific antigen. Percentages do not sum to 100% due to missing data.
aPattern 4, complete balding.
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Table 2. Hazard ratios (95% CI) for prostate cancer in relation to various socio-demographic, anthropometric, and lifestyle factors
at baseline







London 29357 549 1 ref 1 ref
Wales 9075 201 0.87 (0.74–1.02) 0.88 (0.75–1.04)
North-West England 35235 749 0.84 (0.76–0.94) 0.86 (0.76–0.96)
North-Eastern England 25519 480 0.77 (0.68–0.87) 0.78 (0.69–0.89)
Yorkshire & the Humber 32 574 635 0.87 (0.77–0.97) 0.86 (0.77–0.97)
West Midlands 20 957 459 0.99 (0.87–1.12) 0.99 (0.87–1.12)
East Midlands 14 792 326 0.90 (0.78–1.03) 0.89 (0.77–1.02)
South-East England 18423 471 0.98 (0.87–1.11) 0.95 (0.84–1.08)
South-West England 18181 332 0.83 (0.72–0.95) 0.80 (0.70–0.92)
Scotland 15222 373 0.86 (0.75–0.98) 0.87 (0.76–1.00)
Townsend deprivation score, fifths 0.12
One (most affluent) 43 855 1020 1 ref 1 ref
Two 43765 1018 1.02 (0.94–1.11) 1.03 (0.94–1.12)
Three 43808 971 1.00 (0.92–1.10) 1.03 (0.94–1.12)
Four 43 808 842 0.94 (0.86–1.03) 0.98 (0.89–1.07)
Five (most deprived) 43 809 719 0.86 (0.78–0.95) 0.91 (0.82–1.01)
Education 0.665
No qualifications or CSE/O-Level/GCSE or equivalent 29 593 528 1 ref 1 ref
AS/A-Level or equivalent 11 008 201 1.01 (0.86–1.19) 0.99 (0.84–1.17)
Higher education or other professional qualification,
or equivalent
137 027 2797 1.07 (0.98–1.18) 1.04 (0.94–1.14)
Ethnicity o0.001
White 205 839 4374 1 ref 1 ref
Mixed background 1077 13 0.95 (0.55–1.64) 1.01 (0.58–1.74)
Asian 5765 49 0.57 (0.43–0.76) 0.62 (0.47–0.83)
Black 3279 89 2.40 (1.94–2.97) 2.61 (2.10–3.24)
Other 1926 23 0.94 (0.63–1.42) 1.02 (0.67–1.54)
Unemployment 0.719
Paid/self-employment 134 112 1904 1 ref 1 ref
Not in paid/self-employment 85 223 2671 1.00 (0.93–1.07) 1.01 (0.95–1.08)
Lives with a wife or partner 0.331
No 52368 945 1 ref 1 ref
Yes 166 967 3630 1.08 (1.01–1.17) 1.04 (0.96–1.12)
Anthropometric
Height, cm
o170 39918 936 1 ref 1 ref
X170–o175 55888 1227 1.02 (0.94–1.11) 1.00 (0.92–1.09)
X175–o180 60939 1256 1.04 (0.96–1.13) 1.00 (0.92–1.09)
X180–o185 40076 786 1.10 (1.00–1.21) 1.05 (0.95–1.15)
X185 21175 355 1.10 (0.97–1.24) 1.04 (0.92–1.18)
Per 10 cm increase 217 996 4560 1.06 (1.00–1.11) 1.03 (0.98–1.08) 0.307
BMI, kgm2
o25 53707 1142 1 ref 1 ref
X25–o30 107927 2396 0.98 (0.92–1.06) 0.98 (0.92–1.06)
X30–o35 43500 834 0.85 (0.78–0.93) 0.88 (0.81–0.97)
X35 12796 188 0.69 (0.59–0.81) 0.75 (0.64–0.88)
Per 5 kgm 2 increase 217 930 4560 0.89 (0.85–0.93) 0.91 (0.87–0.95) o0.001
Body fatd, fifth cutoff %
o20.5 43 803 816 1 ref 1 ref
X20.5–o24 43270 938 1.02 (0.93–1.12) 1.02 (0.93–1.12)
X24–o26.8 42 957 949 0.95 (0.87–1.05) 0.96 (0.87–1.06)
X26.8–o30.1 41 925 899 0.86 (0.78–0.95) 0.88 (0.80–0.97)
X30.1 42 351 882 0.77 (0.70–0.84) 0.81 (0.73–0.89)
Per 5% increase 214 257 4484 0.90 (0.88–0.93) 0.92 (0.90–0.95) o0.001
Waist circumference,d fifth cutoff cm
o88 49129 939 1 ref 1 ref
X88.1–o93.1 39 113 826 0.99 (0.91–1.09) 1.00 (0.91–1.10)
X93.1–o98.1 49 502 1113 1.00 (0.91–1.09) 1.01 (0.92–1.10)
X98.1–o105.1 37 174 817 0.93 (0.85–1.02) 0.96 (0.87–1.05)
X105.1 43 390 869 0.84 (0.76–0.92) 0.90 (0.82–0.99)
Per 10 cm increase 218 308 4564 0.94 (0.91–0.97) 0.96 (0.93–0.99) 0.016
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Among the lifestyle characteristics analysed in this study,
compared with never smokers, current cigarette smokers (0.85,
0.77–0.95) and former cigarette smokers (0.93, 0.88–0.99) had a
significantly lower risk of prostate cancer, while no association
with risk was observed for alcohol intake or physical activity.
Table 3 shows the HRs of prostate cancer in relation to health
status and prostate-specific factors prior to recruitment, sexual
history, early life factors, and hair colour and balding pattern. Men
with a self-reported diagnosis of diabetes had a lower risk of
incident prostate cancer (HR¼ 0.70, 0.62–0.80). In contrast, men
who had had a PSA test prior to recruitment (1.31, 1.23–1.40), had
any first-degree family history of prostate cancer (1.94, 1.77–2.13),
and who reported that they had been diagnosed with an enlarged
prostate (1.54, 1.38–1.71) had an elevated risk of prostate cancer.
Moreover, compared to men with no family history of prostate
cancer, men with both their father and brother diagnosed with
prostate cancer had an even higher risk of prostate cancer (3.35,
2.33–4.81).
For sexual history factors, men who had no children had a
reduced prostate cancer risk (never vs ever, HR¼ 0.89, 95% CI
0.81–0.97), as did men who reported they had never had sex (never
vs ever, 0.53, 0.33–0.84). Other sexual history characteristics were
not related to prostate cancer risk (Table 3).
Early life factors (relative age of first facial hair, relative age
voice broke, and comparative body size and height at age 10) and
hair colour and pattern were not associated with prostate cancer
risk (Table 3).
For most factors, there was no significant heterogeneity in the
association of prostate cancer risk according to time between
recruitment and diagnosis (o2 and X2 years) (Supplementary
Table 1). However, there was evidence of heterogeneity by time to
diagnosis for the association of prostate cancer risk with ethnicity
(Pheterogeneity¼ 0.001; for black vs white, HR¼ 3.94, 2.85–5.44 for
men diagnosed within 2 years and HR¼ 2.01, 1.49–2.70 for those
diagnosed after 2 years), unemployment (Pheterogeneityo0.001;
HR¼ 1.34, 1.18–1.51 in the first 2 years and HR¼ 0.89, 0.82–
0.97 after 2 years), hypertension (Pheterogeneity¼ 0.018; for yes vs no,
HR¼ 1.12, 1.00–1.24 in the first 2 years and HR¼ 0.95, 0.89–1.02
after 2 years), having had a PSA test prior to recruitment
(Pheterogeneity¼ 0.003; HR¼ 1.51, 1.35–1.70 in the first 2 years and
1.23, 1.14–1.33 after 2 years), and having had enlarged prostate
(Pheterogeneityo0.001; HR¼ 2.16, 1.82–2.56 in the first 2 years and
1.27, 1.10–1.46 after 2 years; Supplementary Table 1).
DISCUSSION
Here we report results on associations with established and
putative risk factors for prostate cancer risk in a large prospective
study of British men. We found that black ethnicity and having
previously had a PSA test, an enlarged prostate, or a family history
of prostate cancer were positively associated with prostate cancer
risk. The risk of being diagnosed with prostate cancer was lower in
those who were of Asian ethnic origin, and in men who had
obesity, smoked cigarettes, had diabetes, and had never had sex.
Time to diagnosis was not a strong modifier of these associations,
although men who had had a PSA test prior to recruitment were
Table 2. ( Continued )





Waist to hip ratio,d fifth cutoff
o0.882 43848 835 1 ref 1 ref
X0.882–o0.918 43787 835 0.87 (0.79–0.96) 0.88 (0.80–0.97)
X0.918–o0.949 43872 982 0.94 (0.86–1.03) 0.96 (0.88–1.06)
X0.949–o0.989 43110 964 0.87 (0.79–0.96) 0.91 (0.83–1.00)
X0.989 43639 948 0.80 (0.73–0.88) 0.87 (0.79–0.96)
Per 0.05 increase 218 256 4564 0.94 (0.92–0.97) 0.97 (0.94–1.00) 0.021
Lifestyle
Smoking 0.004
Never 107 188 2134 1 ref 1 ref
Former 83 154 1991 0.90 (0.85–0.96) 0.93 (0.88–0.99)
Current 27 428 417 0.82 (0.73–0.91) 0.85 (0.77–0.95)
Alcohol intake, g per day
None drinkers 13 874 225 0.83 (0.70–0.99) 0.85 (0.72–1.01)
o1 14577 299 1 ref 1 ref
X1–o10 48187 1030 1.08 (0.95–1.23) 1.04 (0.91–1.18)
X10–o20 46565 1071 1.11 (0.98–1.26) 1.06 (0.93–1.21)
X20 94750 1930 1.02 (0.90–1.15) 1.01 (0.89–1.14)
Per 10 g per day increase 204 723 4340 0.98 (0.96–1.00) 0.99 (0.97–1.01) 0.405
Physical activity, METs per week
Low, 0–o10 60589 1196 1 ref 1 ref
Moderate, X10–o50 103570 2244 1.10 (1.02–1.18) 1.06 (0.99–1.14)
High, X50 47126 975 1.05 (0.96–1.14) 1.01 (0.93–1.10)
Per 20 METs per week increase 211 070 4413 1.00 (0.98–1.03) 1.00 (0.98–1.02) 0.771
Abbreviations: AS¼ advanced subsidiary level; BMI¼body mass index; CI¼ confidence interval; CSE¼Certificate of Secondary Education; GCSE¼General Certificate of Secondary Education;
HR¼hazard ratio; MET¼metabolic equivalent of task; ref¼ reference. Missing and/or unknown values of the exposure of interest were not included in the analyses, but missing and/or
unknown values were assigned to a separate category when the variable was included as a covariate.
aMinimally adjusted model: HRs are stratified by region (10 UK cancer registry regions) and age at recruitment (o45, 45–49, 50–54, 55–59, 60–64, and X65 years) and adjusted for age
(underlying time variable), use as appropriate.
bMultivariable-adjusted model: HRs are stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend deprivation score (fifths, unknown), ethnicity
(white, mixed background, Asian, black, other, and unknown), lives with a wife or partner (no and yes), BMI (o25,X25–o30,X30–o35,X35 kgm 2, unknown), smoking (never, former, current,
and unknown), physical activity (low (0–o10 METs per week), moderate (X10–o50 METs per week), high (X50 METs per week), and unknown), diabetes (no, yes, and unknown), enlarged
prostate (no or unknown, and yes), and family history of prostate cancer (no, yes, unknown), use as appropriate.
cP-values from the multivariable-adjusted model were calculated as follows: P-values for likelihood ratio test for variables with more than two categories were obtained comparing the model
with and without the variable of interest; P-values for dichotomous variables were obtained comparing the reference category to the other category in the model; P-values for trend were
obtained using a pseudo-continuous variable equal to the median value in each category for continuous variables.
dMultivariable-adjusted model as above but without adjustment for BMI.
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Table 3. Hazard ratios (95% CI) for prostate cancer in relation to various health status, prostate specific factors prior to
recruitment, sexual history, and early life factors at baseline







No or unknown 207 969 4343 1 ref 1 ref
Yes 11 366 232 1.05 (0.92–1.20) 1.03 (0.90–1.18)
Hypertension 0.965
No or unknown 104 608 1866 1 ref 1 ref
Yes 114 193 2700 0.99 (0.93–1.05) 1.00 (0.94–1.06)
Diabetes o0.001
No 202 785 4283 1 ref 1 ref
Yes 15 191 270 0.65 (0.57–0.73) 0.70 (0.62–0.80)
Prostate-specific factors prior to recruitment
PSA test o0.001
No 154 265 2283 1 ref 1 ref
Yes 58 497 2009 1.43 (1.35–1.52) 1.31 (1.23–1.40)
Enlarged prostate o0.001
No or unknown 212 242 4216 1 ref 1 ref
Yes 7093 359 1.57 (1.41–1.76) 1.54 (1.38–1.71)
Any first-degree family history of prostate cancer o0.001
No 103 961 1745 1 ref 1 ref
Yes 16 449 599 1.96 (1.78–2.15) 1.94 (1.77–2.13)
Family history of prostate cancer
No 103 961 1745 1 ref 1 ref o0.001
Father or brother 16 098 569 1.91 (1.74–2.10) 1.90 (1.72–2.09)
Father and brother 351 30 3.51 (2.45–5.04) 3.35 (2.33–4.81)
Sexual history
Ever had children 0.007
Yes 171 957 3879 1 ref 1 ref
Never 45 375 669 0.87 (0.80–0.94) 0.89 (0.81–0.97)
Number of children 0.001
1 27 488 517 0.94 (0.85–1.03) 0.95 (0.86–1.04)
2 90 098 2131 1 ref 1 ref
X3 54 371 1231 0.92 (0.86–0.99) 0.93 (0.86–1.00)
Ever had sexual intercourse 0.007
Yes 191 476 3999 1 ref 1 ref
Never 1916 18 0.51 (0.32–0.81) 0.53 (0.33–0.84)
Age at first sexual intercourse, years 0.024
o16 88 078 1781 0.93 (0.86–1.01) 0.97 (0.89–1.06)
X16–o20 48 186 803 1 ref 1 ref
X20–o25 42 717 1125 1.02 (0.94–1.09) 0.98 (0.91–1.06)
X25 12 495 290 0.96 (0.84–1.08) 0.91 (0.80–1.03)
Lifetime number of heterosexual partners 0.013
1 41 598 1126 1 ref 1 ref
X2–o6 65 701 1392 0.96 (0.89–1.04) 0.99 (0.91–1.07)
X6 68 971 1161 0.99 (0.91–1.07) 1.03 (0.95–1.13)
Same-sex intercourse 0.171
No 189 406 3989 1 ref 1 ref
Yes 8576 146 1.07 (0.90–1.26) 1.12 (0.95–1.33)
Lifetime number of same-sex partners 0.964
1 977 18 1 ref 1 ref
X2–o6 1340 25 1.05 (0.57–1.92) 1.05 (0.57–1.92)
X6 1716 22 0.94 (0.50–1.75) 0.93 (0.50–1.74)
Early life
Relative age of first facial hair 0.454
Younger than average 14 262 243 1.01 (0.89–1.15) 1.03 (0.90–1.17)
About average 167 220 3656 1 ref 1 ref
Older than average 27 009 459 0.97 (0.88–1.06) 0.94 (0.86–1.04)
Relative age voice broke 0.548
Younger than average 8769 143 0.99 (0.84–1.17) 1.00 (0.85–1.18)
About average 178 309 3813 1 ref 1 ref
Older than average 11 861 194 0.95 (0.83–1.10) 0.92 (0.80–1.07)
Comparative body size at age 10 0.156
Thinner 75 069 1516 0.94 (0.88–1.00) 0.94 (0.88–1.00)
About average 109 231 2414 1 ref 1 ref
Plumper 29 305 536 0.92 (0.84–1.01) 0.96 (0.88–1.06)
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more likely to be diagnosed with prostate cancer in the first 2 years
of follow-up.
Ethnicity, socio-demographic, anthropometric and lifestyle
factors, and risk of prostate cancer. Our findings for ethnicity
accord with findings from the retrospective PROCESS cohort
study, which has previously shown that compared to white men,
black men in southern England have a greater risk of being
diagnosed with prostate cancer (Ben-Shlomo et al, 2008), while
Asian men have a lower risk (Metcalfe et al, 2008). A cross-
sectional study within the Hospital Episodes Statistics database for
England also showed a higher risk of prostate cancer in men with
black ethnicity (Maruthappu et al, 2015).
Geographic differences in prostate cancer incidence rates
have been observed in the United States (Cook et al, 2015),
indicating that risk factors for prostate cancer occurrence and for
diagnosis may vary geographically. In the current British
study, there were differences in risk between certain geographical
regions. It is possible that some of the regional differences
might be due to differences in detection rates of asymptomatic
prostate cancer (Littlejohns et al, 2016). Socioeconomic
status, education level, employment status, and marital status
(living with a wife or partner) were not associated with prostate
cancer risk.
While we did not observe a significant association of prostate
cancer risk with height, as seen in previous prospective studies
(Pischon et al, 2008; WCRF/AICR, 2014), our results did show that
men with higher BMI and fat mass percentage had a lower risk of
prostate cancer. While two previous prospective studies have used
fat mass measurement from bioimpedance measurements (477
(MacInnis et al, 2003) and 817 incident cases (Wallstrom et al,
2009), respectively), this is to our knowledge the first large
prospective study using bioimpedance to estimate body composi-
tion. Previous prospective investigations have also found a link
between excess adiposity, typically as estimated by BMI or waist
circumference, and a lower risk of overall prostate cancer risk
(Perez-Cornago et al, 2017; WCRF/AICR, 2014). It is possible that
this association might be due to detection bias as in this cohort
men with obesity are less likely to have had a PSA test (Littlejohns
et al, 2016). Moreover, previous studies have reported slightly
lower PSA concentrations in men with high BMI (Bonn et al,
2016). A positive association between adiposity and risk for
aggressive prostate cancer has also been observed in previous
studies (WCRF/AICR, 2014), but data on stage and grade are not
yet available in the UK Biobank cohort.
Findings from the present study of a nearly 15% reduced risk of
prostate cancer in cigarette smokers compared to never smokers
are consistent with results from a 2010 meta-analysis of 24
observational studies (Huncharek et al, 2010). However, men who
were current smokers were markedly less likely to have had a PSA
test than never smokers in UK Biobank (Littlejohns et al, 2016),
and this association might therefore be due to detection bias.
In agreement with findings from a recent meta-analysis
(WCRF/AICR, 2014), alcohol consumption was not related to
prostate cancer risk in the current study. Total physical activity was
also not associated with prostate cancer risk in the current study,
whereas findings from a recent meta-analysis of 46 890 incident
cases, which showed that greater leisure-time physical activity was
associated with a higher risk of prostate cancer (Moore et al, 2016),
although the impact on those results of detection bias was not clear
(i.e., the extent to which PSA testing is associated with health-
conscious behaviour).
Health status, prostate-specific factors prior to recruitment,
sexual history, early life factors, and hair colour and pattern. In
agreement with previous studies (Byrne et al, 2017; Nayan et al,
2016), we found no association between vasectomy status and
prostate cancer risk. In the current study, hypertension was not
linked to prostate cancer risk, although there was some evidence
that it was associated with an increased risk in the first 2 years of
follow-up. A recent meta-analysis has suggested that hypertension
may be related to prostate cancer incidence, but high heterogeneity
Table 3. ( Continued )





Comparative height size at age 10 0.986
Shorter 42 033 865 1.00 (0.93–1.08) 1.00 (0.92–1.08)
About average 119 071 2510 1 ref 1 ref
Taller 53 953 1115 1.01 (0.94–1.09) 1.00 (0.94–1.08)
Hair colour and pattern
Hair colour (natural, before greying in whites) 0.597
Light brown 79 825 1790 1 ref 1 ref
Red 7726 144 0.88 (0.75–1.05) 0.88 (0.74–1.05)
Blonde 19 935 418 0.95 (0.86–1.06) 0.96 (0.86–1.06)
Dark brown 77 304 1523 0.98 (0.91–1.05) 0.97 (0.91–1.04)
Black 16 718 406 1.02 (0.92–1.14) 1.03 (0.92–1.14)
Other 17 152 287 1.01 (0.89–1.14) 0.99 (0.79–1.23)
Hair/balding patternd 0.595
Pattern 1 69 647 1317 1 ref 1 ref
Pattern 2 49 303 903 0.99 (0.91–1.08) 0.99 (0.91–1.07)
Pattern 3 57 208 1388 1.00 (0.93–1.08) 0.99 (0.92–1.07)
Pattern 4 39 051 882 0.95 (0.87–1.03) 0.95 (0.87–1.03)
Abbreviations: CI¼ confidence interval; HR, hazard ratio; PSA¼prostate-specific antigen; ref, reference. Missing and/or unknown values of the exposure of interest were not included in the
analyses, but missing and/or unknown values were assigned to a separate category when the variable was included as a covariate.
aMinimally adjusted model: HRs are stratified by region (10 UK cancer registry regions) and age at recruitment (o45, 45–49, 50–54, 55–59, 60–64, and X65 years) and adjusted for age
(underlying time variable), use as appropriate.
bMultivariable-adjusted model: HRs are stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend deprivation score (fifths, unknown), ethnicity
(white, mixed background, Asian, black, other, and unknown), lives with a wife or partner (no and yes), BMI (o25, X25–o30, X30–o35, X35 kgm 2, and unknown), smoking (never, former,
current, and unknown), physical activity (low (0–o10 METs per week), moderate (X10–o50 METs per week), high (X50 METs per week), and unknown), diabetes (no, yes, and unknown),
enlarged prostate (no or unknown, and yes), and family history of prostate cancer (no, yes, and unknown), use as appropriate.
cP-values from the multivariable-adjusted model were calculated as follows: P-values for likelihood ratio test for variables with more than two categories were obtained comparing the model
with and without the variable of interest; P-values for dichotomous variables were obtained comparing the reference category to the other category in the model; P-values for trend were
obtained using a pseudo-continuous variable equal to the median value in each category for continuous variables.
dPattern 1, no balding; pattern 2, balding at the front; pattern 3, balding on the top of head; pattern 4, complete balding.
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among studies was noted (Liang et al, 2016), and more prospective
data are needed. Our finding that diabetes was associated with a
reduced risk of prostate cancer has been consistently reported in
other cohort studies (Rodriguez et al, 2005; Tsilidis et al, 2015). It
has been suggested that the inverse association between diabetes
and prostate cancer risk might be due to lower circulating
concentrations of IGF-I (Teppala & Shankar, 2010) and/or
testosterone (Grossmann, 2011) or to potential anti-carcinogenic
properties of diabetes medication (Wright and Stanford, 2009).
Information was not available on diabetes type for the current
analyses, but the majority of cases in this age group will be of type
II diabetes (Kirkman et al, 2012).
Increases in the proportion of men undergoing PSA testing in
the UK have led to a large increase in prostate cancer diagnoses
over recent decades (Lilja et al, 2008), and as expected, history
of having had a PSA test was positively associated with prostate
cancer risk in our study. As expected, previous PSA testing was also
more strongly associated with risk in the first 2 years of follow-up,
owing to it being a first-line test in the diagnostic pathway for
men with prostatic symptoms. Similarly, men with an
enlarged prostate were also more likely to be diagnosed with
prostate cancer, particularly within the first 2 years, suggesting
increased likelihood of cancer detection following urological
investigations.
This study found that having a first-degree relative with prostate
cancer doubled the risk of prostate cancer, which is well-
established, although to date only approximately one-third of
this risk is explained by known genetic variants (Benafif & Eeles,
2016). The risk was even higher in men where both the father and
the brother had prostate cancer, although the number of cases
in this category was small (n¼ 30). The remainder of the
excess familial risk may be due to a combination of currently
unidentified genetic variation, shared environmental factors, and
differential detection in family members (e.g., health-seeking
behaviours).
There are few prospective data on sexual history and prostate
cancer risk (Rosenblatt et al, 2001). Our results show that men who
reported never having had sex have a lower prostate cancer risk
than men who had ever had sex. Moreover, men who had not had
children had a lower risk compared to those who had had children.
Men who have not had sex might have erectile dysfunction or low
sexual interest, which are both conditions that have been linked to
reduced circulating androgen levels (Isidori et al, 2005). Observa-
tional epidemiological studies to date have not shown an
association between circulating testosterone and prostate cancer
risk (Roddam et al, 2008), but more data are required to examine
risk in men with very low circulating testosterone levels.
To date it is unclear whether early-life exposures are involved in
prostate cancer aetiology (Sutcliffe & Colditz, 2013; Moller et al,
2015; Sarre et al, 2016), although it has been speculated that
childhood body size or timing of puberty may be related to changes
in prostate tissue in early adulthood (Sutcliffe & Colditz, 2013;
Sarre et al, 2016). Mendelian randomisation studies have shown an
association between genetically determined age at puberty and
higher risk of aggressive prostate cancer risk (Bonilla et al, 2016).
In the current study, however, we found no evidence for
an association between a number of early life factors (relative
age of first facial hair, relative age voice broke, and comparative
height and body size at age 10) and the future risk of prostate
cancer.
It has been hypothesised that pigmentation-related traits may
influence prostate cancer risk, possibly through altered vitamin D
synthesis, owing to a finding in the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study that men with naturally red
hair (which is determined by polymorphisms in the melanocortin-
1-receptor (MC1R) gene) had a lower risk of prostate cancer
compared to men with light brown hair (Weinstein et al, 2013);
however, no significant association between naturally red hair and
prostate cancer risk was observed in the current study. Because of
the influence of the active androgen dihydrotestosterone on both
the growth of prostate cells and on androgenic alopecia, male-
pattern balding has also been suggested as possible risk factor for
prostate cancer, although the findings are inconclusive (Muller
et al, 2013; Zhou et al, 2015a, b; Sarre et al, 2016) and the current
study found no association between balding pattern and prostate
cancer risk.
Study strengths and limitations. This is, to our knowledge, the
largest single prospective study of risk factors for prostate cancer in
British men. The UK Biobank has collected detailed information
on numerous possible prostate cancer risk factors, including risk
factors that few previous studies have examined in detail, such as
body fat mass, sexual history, early life factors, and hair colour and
pattern. In particular, fat mass estimated using bioimpedance is a
better marker of overall adiposity than BMI or waist circumfer-
ence, which does not differentiate between muscle and fat mass.
Moreover, many risk factors, such as adiposity measurements or
blood pressure, were assessed by trained research clinic staff
instead of being self-reported.
Despite the breadth of the exposure information collected at
recruitment, we cannot exclude the possibility of residual
confounding by unknown or unmeasured factors. In addition,
because of the number of tests performed, some of the associations
observed might be due to chance. For some of the rare exposures
(e.g., red hair colour or never having had sexual intercourse), there
are small numbers of exposed cases for robust analysis. This cohort
includes participants from multiple regions, including deprived
areas, but it is not a representative sample of the whole UK
population (Fry et al, 2017). However, it does include participants
with a wide range of exposures for a comprehensive set of
characteristics allowing internally valid and informative compar-
isons of risk by factors of interest. Although the number of
missing values in our cohort is low (o1%), there are some
variables, such as family history of prostate cancer, that have a
higher proportion of missing values. These values may not be
missing at random, for example, participants with family history of
prostate cancer may have replied to this question, while
participants with no family history may have left this question
blank. Finally, risk factors for prostate cancer may differ by tumour
characteristics, but data on tumour stage and Gleason grade were
not available for the current analysis. We will perform analyses by
subgroups of disease aggressiveness when these data become
available.
We have reported a range of established and novel risk factors
that are associated with subsequent prostate cancer risk in this
large UK prospective study. In particular, black ethnicity, having
had a PSA test, an enlarged prostate, and a family history of
prostate cancer were positively associated with prostate cancer risk,
while Asian ethnicity, obesity, smoking status, diabetes, and never
having had children or sexual intercourse were related to a lower
prostate cancer risk. Future research in UK Biobank will include
analyses by disease aggressiveness to explore whether these
associations are due to differences in the likelihood of being
diagnosed and/or differences in the risk of developing clinically
important prostate cancer.
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